Bibliografía del artículo
1. Alman BA. Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy. Pediatr Orthop 25(4):554-6, 2005.
2. Balaban B et al. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil 84:843-850, 2005.
3. Balagopal P et al. Oxandrolone enhances skeletal muscle and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab 209:530-539, 2005.
4. Beenakker EAC et al. Intermittent Prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 62:128-132, 2005.
5. Biggar WD et al. Deflazacort treatment of Duchenne muscular dystrophy. The J Pediatr 138(1):45-50, 2001.
6. Biggar WD et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16(4):249-55, 2006.
7. Bonifati DM et al. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. J Neurol Neurosurg Psychiatry 77(10):1177-9, 2006.
8. Brunelli S et al. Nitric oxide release combined with nonsteroidal antiinflamatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. PNAS 104:264-269, 2007.
9. Bushby K, Griggs R. 145th ENMC International Workshop: Planning for a international trial of steroid dosage regimes in DMD (for DMD) Neuromuscul Disord 17:423-428, 2003.
10. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne muscular dystrophy: A systematic review. BMC Neurology 3:7, 2007.
11. Carter GT et al. Effect of voluntary wheel-running exercise on muscles of the mdx mouse. Neuromuscul Disord 5(4):323-32, 1995.
12. Chakkalakal JV et al. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J 19(8):880-91, 2005.
13. Daftary AS et al. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 119:320-324, 2007.
14. Feder D. Langer AL. Uso dos corticóides no tratamento da Distrofia Muscular de Duchenne Jornal Brasileiro de Medicina 89(1):57-9, 2005.
15. Garrood P et al. Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscul Disord 18:71-73, 2007.
16. Gati I et al. Effects of inhibitors of the arachidonic acid cascade on primary muscle culture from a Duchenne muscular dystrophy patient. Prostaglandins, Leukotrienes and Essential Falley Acids 77:217-223, 2007.
17. Hawker G et al. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne`s muscular dystrophy. Arch Phys Medicine and Rehabilitation 86(2):284-8, 2005.
18. Houde S et al. Deflazacort use in Duchenne muscular dystrophy: An 8-year follow-up. Pediatr Neurol 38:200-206, 2008.
19. Hussein MR et al. The effect of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol 87(6):451-61, 2006.
20. Kinali M et al. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol 11:160-166, 2007.
21. King WM et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68(19):1607-13, 2007.
22. Kocabas S et al. Anesthesic management of a child with Duchenne muscular dystrophy undergoing correction of Fallot's Tetralogy. Pediatric Anesthesia 18:439-452, 2008.
23. Markham LW et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26:768-771, 2005.
24. Markham LW et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 18:365-370, 2008.
25. Mavrogeni S et al. Effect og deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: A magnetic resonance imaging study. Eur J Paediat Neurol doi:10.1016/j.ejpn.2008.02.006, 2008.
26. Miura P et al. IRES-Mediated Translation of Utrophin a is enhance by glucocorticoid treatment in skeletal muscle cell. PLoS ONE 3(6)e2309. doi:10.1371/journal.pone0002309, 2008.
27. Moxley III RT ET al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standars Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64:13-20, 2005.
28. Muenster T et al. Reversal of rocuronium-induced neuromuscular blockade by pyridostigmine in patients with Duchenne muscular dystrophy. Pediat Anesthesia 18:251-25, 2008.
29. Parreira SLS et al. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arq Neuropsiquiatria 65(2-A):254-250, 2007.
30. Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurological Sciences 129:97-105, 1995.
31. Pradham S. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253(10):1309-16, 2006.
32. Radley HG et al. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. IJBCB 39:469-477, 2007.
33. Söderpalm AC et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 17:919-928, 2007
34. Stober JB. Therapeutics in Duchenne muscular dystrophy. NeuroRx 3(2):225-34, 2006.